Endothelin-1 stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by endothelin receptor transactivation of the transforming growth factor-β type I receptor

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 4, 2010, Pages 360-368

  Little, Peter J ^a,b   Burch, Micah L ^a,b   Getachew, Robel ^a   Al Aryahi, Sefaa ^a   Osman, Narin ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

endothelin receptors; glycosaminoglycans; proteoglycans; receptor transactivation; receptors; transforming growth factor

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BIGLYCAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; GLYCOSAMINOGLYCAN; PROTEOGLYCAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PHOSPHOSMAD2C; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOGLYCAN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

BENZAMIDES; CELLS, CULTURED; DIOXOLES; ENDOTHELIN-1; GLYCOSAMINOGLYCANS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; RECEPTORS, ENDOTHELIN; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SULFONAMIDES; TRANSCRIPTIONAL ACTIVATION;

EID: 77958504428     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181ee6811     Document Type: Article

References (46)

1. Lefkowitz RJ. Seven transmembrane receptors: something old, something new. Acta Physiol (Oxf). 2007;190:9-19.
2. Smith NJ, Luttrell LM. Signal switching, crosstalk, and arrestin scaffolds: novel G protein-coupled receptor signaling in cardiovascular disease. Hypertension. 2006;48:173-179.
3. Little PJ, Ivey ME, Osman N. Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. Curr Vasc Pharmacol. 2008;6:195-203.
4. Bobik A, Grooms A, Millar JA, et al. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol. 1990;258:C408-C415.
5. Little PJ, Neylon CB, Tkachuk VA, et al. Endothelin-1 and endothelin-3 stimulate calcium mobilization by different mechanisms in vascular smooth muscle. Biochem Biophys Res Commun. 1992;183: 694-700.
6. Higashi Y, Noma K, Yoshizumi M, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009;73:411-418.
7. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J. 2009;73:595-601.
8. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
9. Shraga-Levine Z, Sokolovsky M. Functional coupling of G proteins to endothelin receptors is ligand and receptor subtype specific. Cell Mol Neurobiol. 2000;20:305-317.
10. McCudden CR, Hains MD, Kimple RJ, et al. G-protein signaling: back to the future. Cell Mol Life Sci. 2005;62:551-577.
11. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308:512-517.
12. Daub H, Weiss FU, Wallasch C, et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996;379: 557-560.
13. Gavi S, Shumay E, Wang HY, et al. G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. Trends Endocrinol Metab. 2006;17:48-54.
14. Ivey ME, Little PJ. Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways. Thromb Res. 2008;123:288-297.
15. Ballinger ML, Ivey ME, Osman N, et al. Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteogly-cans with increased binding to LDL. Atherosclerosis. 2009;205: 451-457.
16. Dadlani H, Ballinger ML, Osman N, et al. Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle. J Biol Chem. 2008;283:7844-7852.
17. Bobik A, Agrotis A, Kanellakis P, et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation. 1999;99:2883-2891.
18. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577-584.
19. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685-700.
20. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001; 411:355-365.
21. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67: 753-791.
22. Ikedo H, Tamaki K, Ueda S, et al. Smad protein and TGF-beta signaling in vascular smooth muscle cells. Int J Mol Med. 2003;11:645-650.
23. Schonherr E, Jarvelainen HT, Kinsella MG, et al. Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb. 1993;13:1026-1036.
24. Little PJ, Tannock L, Olin KL, et al. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol. 2002; 22:55-60.
25. Nakashima Y, Fujii H, Sumiyoshi S, et al. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol. 2007;27: 1159-1165.
26. Ballinger ML, Nigro J, Frontanilla KV, et al. Regulation of glycosami-noglycan structure and atherogenesis. Cell Mol Life Sci. 2004;61: 1296-1306.
27. Little PJ, Ballinger ML, Osman N, et al. Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vasc Health Risk Manag. 2007;3:1-8.
28. Liu Y, Ren W, Warburton R, et al. Serotonin induces Rho/ROCK-dependent activation of smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J. 2009;23:2299-2306.
29. Ballinger ML, Osman N, Hashimura K, et al. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med. 2010;14: 1408-1418.
30. Neylon CB, Little PJ, Cragoe EJ Jr, et al. Intracellular pH in human arterial smooth muscle. Regulation by Na+/H+ exchange and a novel 5-(N-ethyl-N-isopropyl)amiloride-sensitive Na(+)-and HCO3(-)-dependent mechanism. Circ Res. 1990;67:814-825.
31. Nigro J, Dilley RJ, Little PJ. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis. 2002;162:119-129.
32. Tannock L, Little PJ, Wight TN, et al. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res. 2002;43:149-157.
33. Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis. 2008;199:237-247.
34. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434-2440.
35. Matsumaru K, Kashimura H, Hassan M, et al. Bosentan, a novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions induced by indomethacin and HCl in the rat: role of endogenous endothelin-1. J Gastroenterol. 1997;32:164-170.
36. Yang Z, Krasnici N, Luscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation. 1999;100:5-8.
37. Mori Y, Ishida W, Bhattacharyya S, et al. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum. 2004;50: 4008-4021.
38. Wasteson A, Uthne K, Westermark B. A novel assay for the biosynthesis of sulphated polysaccharide and its application to studies on the effects of somatomedin on cultured cells. Biochem J. 1973;136:1069-1074.
39. Liu IM, Schilling SH, Knouse KA, et al. TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J. 2009;28:88-98.
40. Iwasaki H, Eguchi S, Marumo F, et al. Endothelin-1 stimulates DNA synthesis of vascular smooth-muscle cells through transactivation of epidermal growth factor receptor. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S182-S184.
41. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783-2810.
42. Natarajan K, Berk BC, Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. Methods Mol Biol. 2006; 332:51-77.
43. Wang C, Wu LL, Liu J, et al. Crosstalk between angiotensin II and platelet derived growth factor-BB mediated signal pathways in cardiomyocytes. Chin Med J (Engl). 2008;121:236-240.
44. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci. 2005; 118:3573-3584.
45. Lee MK, Pardoux C, Hall MC, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007;26: 3957-3967.
46. Lew ED, Furdui CM, Anderson KS, et al. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal. 2009;2:ra6.